Warning: The NCBI web site requires JavaScript to function. more...
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.
Faries DE, Nyhuis AW, Ascher-Svanum H.
Cost Eff Resour Alloc. 2009 May 27;7:11.
Related citations
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.
BMC Psychiatry. 2009 Sep 2;9:54.
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK, Kruzikas DT, McLaughlin TP.
J Manag Care Pharm. 2008 Jun;14(5):426-41.
Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.
J Ment Health Policy Econ. 2003 Jun;6(2):67-75.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.
Appl Health Econ Health Policy. 2008;6(1):41-53.
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A.
CNS Drugs. 2004;18(3):157-64.
Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.
Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ.
Pharmacoeconomics. 2004;22(1):1-8. Review.
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.
Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.
Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D, Bond GR, Huxley P, Tyrer P.
Health Technol Assess. 2001;5(21):1-75. Review.
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
Health Technol Assess. 2001;5(32):1-195. Review.
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.
Pharmacoeconomics. 2008;26(4):341-58.
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
Curr Med Res Opin. 2008 May;24(5):1399-405. Epub 2008 Apr 7.
A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system.
Altavela JL, Jones MK, Ritter M.
J Manag Care Pharm. 2008 Nov-Dec;14(9):831-43.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP, Schaecher K, Cannon HE, Speckman M.
J Manag Care Pharm. 2008 Jun;14(5):442-50.
Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP.
J Manag Care Pharm. 2009 Oct;15(8):669-82.
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.
Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. Review.
Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Essock SM, Frisman LK, Covell NH, Hargreaves WA.
Arch Gen Psychiatry. 2000 Oct;57(10):987-94.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on